Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

• Healthy male volunteer in the age between 19 and 55 years old.
• Body mass index (BMI) in the range of 18.5 to 27.0 kg/m2
• Understand the requirements of the study and voluntarily consent to participate in the study.

Exclusion Criteria:

• Previous history or present of clinically significant digestive , cardiovascular, respiratory, psychiatric, endocrine, hepatobiliary, renal disease.
• History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption.
• Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
• Subjects whose clinical laboratory test values are outside the accepted normal range. Especially, ASTor ALT >1.5 times of the Upper Normal Limit or total bilirubin > 1.5 times of the Upper Normal Limit
• Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and Syphilis regain test
• Participation in any clinical investigation within 3 months prior to study drug administration
• Subjects with whole blood donation within 60 days or component blood donation within 30days or blood transfusion within 30days prior to the first dosing.
• SBP ≥ 140 mmHg or\< 115 mmHg, DBP ≥ 90 mmHg or \< 70 mmHg
• Caffeine > 400mg/day
• Alcohol > 30g/day
• Cigarette > 10 cigarettes/day.
• Subjects who are judged unsuitable by investigators